Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      

This page is updated frequently with new Receptor-related patent applications.




Date/App# patent app List of recent Receptor-related patents
06/23/16
20160182744 
 Printing system and printing instruction apparatus patent thumbnailPrinting system and printing instruction apparatus
A printing instruction apparatus includes, a print data generator that generates first print data corresponding to document data of a first copy in document data and second print data corresponding to document data of second and subsequent copies in the document data, according to a print request for multiple copies of the document data, and a transmitter that transmits the generated first print data to the printing apparatus. A printing apparatus includes, a receptor that receives the transmitted first print data, a printer that performs printing according to the received first print data, and an operator that receives a print execution operation corresponding to a printed result according to the first print data.

06/23/16
20160181539 
 Systems and process for forming carbon nanotube sensors patent thumbnailSystems and process for forming carbon nanotube sensors
A system for forming a functionalized sensor for sensing a molecule of interest includes at least one single or multi-wall carbon nanotube having a first and a second electrode in contact therewith on a substrate; a third electrode including a decorating material on the substrate a predetermined distance from the at least one single or multi-wall carbon nanotube having a first and a second electrode in contact therewith, wherein the decorating material has a bonding affinity for bioreceptors that react with the molecule of interest; and wherein applying a voltage to the third electrode causes the decorating material to form nanoparticles of the decorating material on the at least one single or multi-wall carbon nanotube.. .

06/23/16
20160178622 
 Aptamer-based biosensing patent thumbnailAptamer-based biosensing
The present disclosure relates to a biosensor device for detecting a predetermined target analyte. The device comprises a substrate.

06/23/16
20160178616 
 T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds patent thumbnailT1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
Also the present invention relates to the use of hetero-oligomeric taste receptors comprising t1r1/t1r3 and t1r2/t1r3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli.. .

06/23/16
20160178344 
 Wafer to wafer alignment patent thumbnailWafer to wafer alignment
Wafer to wafer alignment which includes a first semiconductor wafer and a second semiconductor wafer. The first and second semiconductor wafers have selectively-activated alignment arrays for aligning the first semiconductor wafer with the second semiconductor wafer.

06/23/16
20160177926 
 System and  securing a conductive cable within a wind turbine rotor blade patent thumbnailSystem and securing a conductive cable within a wind turbine rotor blade
The present disclosure is directed to a system and method for securing a lightning protection cable (e.g. A conductor) of a lightning protection system within a wind turbine rotor blade.

06/23/16
20160177396 
 Comprehensive and comparative flow cytometry-based methods for identifying the state of a biological system patent thumbnailComprehensive and comparative flow cytometry-based methods for identifying the state of a biological system
The present disclosure provides comprehensive and comparative flow cytometry-based methods for identifying the state of a biological system by identifying the phenotype of cells and correlating the phenotype with the gene expression profile of the cells, which is indicative of cell function. The cells can be immune cells from a subject suffering from immune-mediated disorders that result in imbalance of the immune system and impair a subject's ability to recognize self-antigens or fight infection or disease.

06/23/16
20160177390 
 Genetic and image biomarkets associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease patent thumbnailGenetic and image biomarkets associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease
The present disclosure is based on the identification of biomarkers of combined genetic variants and imaging measurements, in predicting faster decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease. The present disclosure provides a method of treating a patient with alzheimer's disease (ad) or a subject susceptible to developing ad, comprising: (a) assaying a sample obtained from an early-stage ad patient or a subject susceptible to developing ad for the presence of a brain-derived neurotrophic factor (bdnf) gene mutation and/or a protein tyrosine phosphatase receptor-type, z polypeptide 1 (ptprz1) gene mutation; (b) determining whether the patient or subject is positive for brain amyloid-beta (aβ), wherein the presence of brain aβ in combination with the bdnf gene and/or ptprz1 gene mutation correlates with a prediction of rapid cognitive decline; and (c) treating the patient or subject with early and aggressive therapy appropriate to treat ad with rapid cognitive decline..

06/23/16
20160177261 
 Methods of inducing and preventing neurofibromatosis in schwann cells patent thumbnailMethods of inducing and preventing neurofibromatosis in schwann cells
The invention provides a method of inducing neurofibromatosis type 2 (nf2) in schwann cells. The method comprises contacting the cells with laminin-1 so as to bind α6β1 integrin sufficiently to activate endogenous kinase cdc42-pak; and phosphorylating schwannomin-s518 in the cells by the activated kinase, effectively inactivating.

06/23/16
20160176985 
 Humanized monoclonal antibodies and methods of use patent thumbnailHumanized monoclonal antibodies and methods of use
The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor ccr4. This antibody is derived from mab 1567 and recognizes the same epitope.

06/23/16
20160176973 

Binding molecules for bcma and cd3


The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of bcma, and the second binding domain is capable of binding to the t cell cd3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector.

06/23/16
20160176972 

Prion protein as a receptor for amyloid-beta oligomers


The invention provides methods of inhibiting suppression of long term potentiation, improving acute memory retention and spatial memory performance and treating alzheimer's disease by administration of a prpc antagonist or combinations thereof. Additionally, this invention provides pharmaceutical kits comprising, and methods for making and using, such combinations, as well as methods of identifying molecules that could function as prpc antagonists..

06/23/16
20160176971 

Methods and compositions relating to anti-il-21 receptor antibodies


The present invention provides compositions and methods relating to antigen binding proteins against il-21 receptor.. .

06/23/16
20160176963 

Antibodies to tigit


The present invention provides antibodies, or antigen binding fragments thereof, that bind to human tigit (t cell immunoreceptor with ig and itim domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the pd-1/pd-l1 interaction.

06/23/16
20160176961 

Thrombopoietin receptor ligands for neuroprotection


Methods for the treatment of an ischemic event (e.g., stroke) that creates or embodies a risk of neurological damage in cns sites by administration of a thrombopoietin receptor ligand.. .

06/23/16
20160176944 

Oligomeric receptor ligand pair member complexes


This invention concerns an oligomeric receptor-ligand pair member in general and an oligomeric mhc-peptide complex in particular and a method of labeling, detecting and separating mammalian t cells according to the specificity of their antigen receptor by use of the oligomer. The invention further concerns a method of targeting the oligomeric receptor-ligand pair member complexes to target molecules of the surface of a target cell in order to present antigens on the target cell.

06/23/16
20160176941 

Cd40l collectin fusion proteins


The present invention refers to a fusion protein comprising a tnf-superfamily (tnfsf) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof.

06/23/16
20160176930 

Mu opioid receptor agonist analogs of the endomorphins


The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated amino acid and (ii) a d-amino acid substitution in position 2.

06/23/16
20160176929 

Bradykinin receptor modulators and use thereof


The present invention relates generally to novel biological and purified peptides as bradykinin receptor modulators for use in the treatment and/or prevention of inflammatory diseases, pain, hyperalgesia, cardiovascular and/or cerebral ischemic diseases, in a subject in need thereof.. .

06/23/16
20160176927 

Peptide for suppressing osteoclast differentiation and use thereof


The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (il)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of nf-κb and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-b ligand (rankl)-rank signaling pathway, and suppresses the expression of a rankl or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (trap), cathepsin k, or tnf receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration.

06/23/16
20160176925 

Melanocortin receptor ligands modified with hydantoin


The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.. .

06/23/16
20160176924 

Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction


The present invention is directed to the provision of small molecule inhibitors of the psd-95/nmda receptor interaction, employing an undecapeptide corresponding to the c-terminal of the nmda as a template for finding lead candidates. A compound (nmdar/psd-95 inhibitor) of the invention includes a peptide or peptide analogue comprising at least four peptide bonded residues having the sequence ytxv or ysxv, wherein y is selected from among e, q, and a, or an analogue thereof, and x is selected from among a, q, d, n, n-me-a, n-me-q, n-me-d, and n-me-n or an analogue thereof, wherein an amino-terminal residue of the peptide is n-alkylated.

06/23/16
20160176891 

Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents


Are provided. Pharmaceutical compositions comprising either the compound of formula i or formula ii are disclosed.

06/23/16
20160176890 

Oral pharmaceutical compositions of buprenorphine and another opioid receptor agonist


The present invention is directed to oral pharmaceutical compositions of buprenorphine and it pharmaceutically acceptable salts and the use thereof.. .

06/23/16
20160176879 

Novel hydroximic acid derivative and medical application thereof


The present invention relates to a kind of new hydroximic acid derivatives, in particular, hydroximic acid derivatives of pyrazolopyrimidine and their medical applications, which have inhibition to histone deacetylase 1 and two kinds of tyrosine kinases (vascular endothelial cell growth factor receptors as well as platelet-derived growth factor receptors) simultaneously, and thus can be used for treatment of diseases related to those three kinds of enzymes. This kind of compounds both exerts a synergistic effect sufficiently to increase biological activity, and avoids problems caused by different properties and metabolisms, therefore is more practical and has good prospects..

06/23/16
20160176875 

Spirocyclic ebi2 modulators


Provided herein are small molecule epstein-barr virus-induced g-protein coupled receptor 2 (ebi2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, ebi2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease..

06/23/16
20160176863 

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists


Wherein r1, r2, r3, a, and g are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds..

06/23/16
20160176862 

1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives


Wherein x, y, r1, r2, r3, r4 and r5 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the cxcr3 receptor.. .

06/23/16
20160176861 

Hydroxy containing fxr (nr1h4) modulating compounds


The present invention relates to compounds which bind to the nr1h4 receptor (fxr) and act as agonists of fxr. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds..

06/23/16
20160176858 

Oxazole orexin receptor antagonists


The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.

06/23/16
20160176851 

Antagonists of prostaglandin ep3 receptor


Provided herein are antagonists of prostaglandin ep3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.. .

06/23/16
20160176841 

Selectively substituted quinoline compounds


Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (sle) and lupus nephritis.. .

06/23/16
20160176831 

11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists


The disclosure includes compounds and pharmaceutically acceptable salts of formula (i). Certain compounds and salts of formula (i) are selective inhibitors of the dopamine d2 receptor.

06/23/16
20160176816 

Novel biphenyl derivative and preparing same


The present invention provides novel biphenyl derivatives, isomers thereof, or pharmaceutically acceptable salts thereof, methods for preparing the same, and a pharmaceutical composition containing the same. The novel biphenyl derivatives, isomers thereof, or pharmaceutically acceptable salts thereof, as disclosed in the present invention, act as muscarinic m3 receptor antagonists, and thus are useful for the prevention or treatment of a disease selected from the group consisting of chronic obstructive pulmonary disease, asthma, irritable bowel syndrome, urinary incontinence, rhinitis, spasmodic colitis, chronic cystitis, alzheimer's disease, senile dementia, glaucoma, schizophrenia, gastroesophageal reflux disease, cardiac arrhythmia, and hyper-salivation syndromes..

06/23/16
20160175485 

Combination therapy to promote wound healing


Methods for increasing and/or promoting wound healing, wound re-epithelialization and dermal regeneration of epithelial tissues and cutaneous wounds by administration to a subject of an extracellular matrix scaffold or scaffold for dermal regeneration (sdr) populated with beta adrenergic receptor antagonist pre-conditioned mesenchymal stem cells (mscs) are provided. Compositions and kits comprising an extracellular matrix scaffold (ecms) populated with beta adrenergic receptor antagonist pre-conditioned mesenchymal stem cells (mscs) are also provided..

06/23/16
20160175450 

Drug delivery of temozolomide for systemic based treatment of cancer


The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (tmz) by conjugating tmz in its hydrazide form to a polymalic acid platform.

06/23/16
20160175400 

Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides


Methods are provided for administering an extended half-life glp-1/gip coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.. .

06/23/16
20160175399 

Il-13 receptor binding peptides


A targeting peptide that specifically binds to an il13 receptor (e.g., wherein said targeting peptide is not an il13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule.

06/23/16
20160175398 

Chimeric immunoreceptor useful in treating human cancers


The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of t lymphocytes, direct t cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific.

06/23/16
20160175384 

Melanotropin ligands for skin care


A melanocortin 1 receptor (mc1r) peptide ligand-elastic vesicle complex. The mc1r peptide ligand is modified by coupling the mc1r ligand to a functionality or linker, such as a click functionality, for conjugation to a surface or agent.

06/23/16
20160175383 

Calcimimetics and methods for their use


Methods for treating subjects suffering from chronic kidney disease-mineral and bone disorder or other disorders resulting in primary or secondary hyperparathyroidism are described. The methods are effective in reducing serum parathyroid hormone (pth) levels and calcium levels in patients who undergo hemodialysis.

06/23/16
20160175382 

Compositions and methods for inducing urinary voiding and defecation


Methods, pharmaceutical formulations, and kits are provided for using neurokinin 2 receptor agonists to effectuate voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing voiding of urine and defecation in mammals that do not have a voiding dysfunction such as, for example, in a person who is comatose and may void unconsciously or in a pet at a convenient location at a specific time.

06/23/16
20160175370 

Targeting of herpes simplex virus to specific receptors


The invention relates to engineered herpes simplex virus (hsv) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such hsv particles are provided.

06/23/16
20160175362 

Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells


Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof.

06/23/16
20160175361 

Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells


Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof.

06/23/16
20160175359 

Methods for controlled activation or elimination of therapeutic cells


The technology relates in part to methods for controlling the activity or elimination of therapeutic cells using multimerization of proteins to manipulate individual protein-protein interactions in therapeutic cells, for example, by activating or eliminating cells used to promote engraftment, to treat diseases or condition, or to control or modulate the activity of therapeutic cells that express chimeric antigen receptors or recombinant t cell receptors.. .

06/23/16
20160175349 

Brain function-improving composition


Provided is a brain function-improving composition which can inhibit binding of homocysteic acid to a receptor (nmda receptor) and, at the same time, decrease the binding ability of homocysteic acid per se to the receptor to thereby improve reduction in the brain function caused by the toxicity of homocysteic acid. The brain function-improving composition comprises 0.3-0.5 part by weight of a cinnamic acid derivative compound and 0.5-0.7 part by weight of a calcium hydride powder.

06/23/16
20160175320 

Compositions, methods and kits for treating cancer


Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: Δ12-prostaglandin j3 or a derivative thereof, or a prostaglandin d receptor (dp) agonist. The compositions may further include a second anti-cancer drug.

06/23/16
20160175314 

1,2,4-triazine-4-amine derivatives


According to the invention there is provided a compound of formula a1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the a1-a2b or, particularly, the a2a receptor wherein the compound of formula a1 has the structure, wherein, a represents cy1 or heta; cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which cy1 group is optionally substituted by one or more r4a substituents; heta represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from o, s and n, which heterocyclic group may comprise one, two or three rings and which heta group is optionally substituted by one or more r4b substituents; b represents a cy2 or hetb; cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which cy2 group is optionally substituted by one or more r4c substituents; hetb represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from o, s and n, which heterocyclic group may comprise one or two rings and which heta group is optionally substituted by one or more r4d substituents. .

06/23/16
20160175289 

Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof


And stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the formula i compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors..

06/23/16
20160175286 

Selective at2 receptor agonists for use in treatment of cachexia


The present invention is directed to selective at2 receptor agonist or a pharmaceutically acceptable salt thereof for use in treatment of cachexia, preferably for use in treatment of cancer cachexia.. .

06/23/16
20160175284 

Estrogen receptor modulators and uses thereof


And stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors..

06/23/16
20160175283 

Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies


The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer.

06/23/16
20160175282 

Sphingosine 1 phosphate receptor moduators and their use to treat muscle inflammation


Sip receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.. .

06/23/16
20160175278 

Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics


Provided herein are novel agents that modulate ahr activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise ahr inhibitors or non-constitutive ahr agonists of formula (i) and (ii) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness..

06/23/16
20160175266 

Nmda receptor antagonist formulation with reduced neurotoxicity


The present invention is directed to pharmaceutical compositions of effective amounts of nmda receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity.

06/23/16
20160175263 

Pharmaceutical composition for preventing or treating diabetes mellitus, preventing or treating diabetes mellitus, and screening for diabetes mellitus therapeutic agent


Provided are a pharmaceutical composition including geraniol or a pharmaceutically acceptable salt thereof as an active ingredient for use in preventing or treating diabetes mellitus, a method of preventing or treating diabetes mellitus or a complication due to diabetes mellitus of an individual, in which the method includes administering the individual with a pharmaceutical composition comprising geraniol or a pharmaceutically acceptable salt thereof as an active ingredient and inducing an olfactory stimulation to the individual using the pharmaceutical composition, and a screening method of an antidiabetic agent that may include contacting a cell expressing an olfactory receptor with a test material; measuring a level of expression of glucagon-like peptide-1 (glp-1) secreted from the cell; and determining the test material, when the test material promotes expression of glp-1, as a candidate material of an antidiabetic agent. In addition, a quasi-drug composition and a cosmetic composition including geraniol for uses are provided..

06/23/16
20160175251 

Yeast cell wall particles for receptor-targeted nanoparticle delivery


The present invention generally relates to yeast cell wall microparticles loaded with nanoparticles for receptor-targeted nanoparticle delivery. In particular, the present invention relates to trapping nanoparticles either on the surface or inside a yeast glucan particles, for example, yeast glucal particles.

06/23/16
20160174831 

Ophthalmic apparatus, photoreceptor cell detection method and program


An ophthalmic apparatus includes an image acquiring unit configured to acquire an eye fundus image of an eye to be examined, a candidate acquiring unit configured to acquire a plurality of candidate points for a photoreceptor cell in the eye fundus image based on brightness values of the eye fundus image, a first acquiring unit configured to acquire a first feature value of a first candidate point included in the plurality of candidate points based on a distance between the first candidate point and a second candidate point included in the plurality of candidate points, and a determining unit configured to determine whether the first candidate point is a point representing the photoreceptor cell or not based on the first feature value.. .

06/16/16
20160172885 

Charging system


A charging system for a battery powered device is described. The system has a battery charger with charging terminals for a battery.

06/16/16
20160170305 

Imaging system with electrophotographic patterning of an image definition material and methods therefor


A system comprises an electrophotographic subsystem, a transfer subsystem, an imaging member, and an inking subsystem. The electrophotographic subsystem comprises a photoreceptor, a charging subsystem, an exposure subsystem, and a development subsystem.
Xerox Corporation


06/16/16
20160169890 

Tracking donor-reactive tcr as a biomarker in transplantation


The invention provides for the use of deep sequencing of the t-cell receptor beta cdr3 to identify, then track donor specific and/or recipient specific t cells in blood, urine and/or end-organs of transplant recipients.. .
Adaptive Biotechnologies Corp.


06/16/16
20160169878 

Detection of analytes using metal nanoparticle probes and dynamic light scattering


Disclosed herein are systems and methods for detecting chemical species, biomolecules and biotargets (analytes) using receptor functionalized metal nanoparticles and dynamic light scattering.. .
University Of Central Florida Research Foundation, Inc.


06/16/16
20160169873 

Label-free detection of small and large molecule interactions, and activities in biological systems


A system for quantitative detection and analysis of the interactions of molecules with molecular receptors on the surfaces of biological cells based on detecting a mechanical deformation in the membrane of a cell associated with the molecular interactions, which works for both large and small molecules. The mechanical deformation can be detected with high precision in real time from an optical image of the cell with a differential detection method.
Arizona Board Of Regents On Behalf Of Arizona State University


06/16/16
20160168646 

Method for predicting response to breast cancer therapeutic agents and treatment of breast cancer


Methods for treating triple negative breast cancer with an androgen receptor inhibitor are provided, as well as methods for screening for the likelihood of the effectiveness of such treatment.. .
Medivation Prostate Therapeutics, Inc.


06/16/16
20160168571 

Cpg-oligodeoxynucleotide, immunogenic composition comprising the same, and methods for preparing the composition and stimulating immune response thereby


Cpg-oligodeoxynucleotides (cpg-odn), as potent immune stimuli developed for using as adjuvant in different species, are disclosed herein. Tlr9 is the cellular receptor for cpg-odn, and current developed cpg-odn has low activity to rabbit tlr9.
National Health Research Institutes


06/16/16
20160168268 

Anti-immunoglobulin e antibodies and methods of using thereof


The present disclosure provides antibodies that specifically bind to circulating and receptor-bound ige and inhibit ige-mediated cell activation. The antibodies find use in various treatment, diagnostic, and monitoring applications, which are also provided..
Sixal, Inc.


06/16/16
20160168256 

Monoclonal antibody and a method thereof


The present invention relates to a humanized igg1 isotype anti-cd6 antibody (t1h) that binds to the scavenger receptor cysteine-rich (srcr) domain 1 (d1) of cd6 present on the surface of thymic epithelial cells, monocytes, activated t cells and a variety of other cells types.. .
Biocon Limited


06/16/16
20160168255 

Bag3 receptor binding molecules for use as a medicament


The present invention relates to the use of bag3 receptor-binding molecules as a medicament, in particular for use in the treatment of diseases of an immune, inflammatory, cardiovascular, neoplastic and/or degenerative nature.. .
Biouniversa S.r.l.


06/16/16
20160168253 

Therapeutic fusion protein


The invention relates to a fusion protein comprising an antibody directed to aβ, a monovalent binding entity which binds to a blood brain barrier receptor and a neprilysin.. .
Hoffmann- La Roche Inc.


06/16/16
20160168251 

Antibodies for guanylyl cyclase receptors


Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.. .
Morphosys Ag


06/16/16
20160168246 

Method for treating tumors that possess the cck-c receptor with the 3b9.1 monoclonal antibody


Human pancreatic cancer cells possess a distinct plasma membrane cck receptor variant that can be differentiated from the classic cck-b receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer..

06/16/16
20160168245 

Trpm4 channel inhibitors for stroke treatment


The present invention relates to methods for treating ischemic stroke including extension of the therapeutic time window for reperfusion. More particularly, the invention relates to a method of treating stroke in a subject by inhibiting the transient receptor potential melastatin 4 (trpm4) channel.
Singapore Health Services Pte Ltd


06/16/16
20160168233 

Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets


The present invention relates to methods for treating and preventing staphylococcus aureus infection and/or a condition resulting from a s. Aureus infection in a subject that involves administering compositions that inhibit s.

06/16/16
20160168225 

Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists


The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. .
Sanofi


06/16/16
20160168201 

Methods and compositions for the treatment of gastrointestinal disorders


Compositions and related methods for treating ibs and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (gerd), duodenogastric reflux, crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase c (gc-c) receptor..
Ironwood Pharmaceuticals, Inc.


06/16/16
20160168183 

Conjugates containing hydrophilic spacer linkers


Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.. .
Endocyte, Inc.


06/16/16
20160166713 

Immune-compromised zebrafish


Genetically-modified zebrafish lacking one or more immune-related genes, and the use thereof, e.g., in cell or tissue transplantation methods or in stem cell biology. In a first aspect, the invention provides a genetically-modified fish whose genome is homozygous for engineered or induced genetic alteration, e.g., an alteration that changes the sequence of the genomic ona resulting in insertion and deletion of nucleotides that disrupt protein function or shift the frame of translation leading to premature protein termination, in one or more immune-related genes selected from the group consisting of: foxn1, rag2, jak3, prkdc, and interleukin 2-receptor gamma a and (il2rga and il2rgb),wherein the genetic alteration results in an inactivation (i.e., loss of expression or function) of both alleles of the immune-related gene..
The General Hospital Corporation


06/16/16
20160166687 

Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate


The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent.
Irm Llc


06/16/16
20160166681 

Toll-like receptor agonists


Compounds described herein can be used for therapeutic purposes. The compounds can be tlr agonists, such as tlr7 or tlr8 agonists.

06/16/16
20160166669 

Antigenic compositions and methods


Multilayer films comprised of polypeptide epitopes and a toll-like receptor ligand. The multilayer films are capable of eliciting an immune response in a host upon administration to the host.
Artificial Cell Technologies, Inc.


06/16/16
20160166667 

Divalent vaccine compositions and the use thereof for treating tumors


The invention describes vaccine compositions combined in the same proportion with the extracellular domains of growth factor receptors her1 and her2 or fragments thereof and furthermore very small size proteoliposomes derived from proteins of the outer membrane of neisseria meningitidis and gm3 ganglioside (vssp-gm3), administered subcutaneously. The disclosed compositions, which induce the production of antibodies are used for the treatment of malignancies and offer advantages because they completely remove the tumor mass thus preventing tumor regression due to the emergence of resistant variants..
Centro De Inmunologia Molecular


06/16/16
20160166639 

Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases


A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (pacap) which can both agonize pac1 receptors, causing neuroprotective effects, and antagonize vpac receptors, causing anti-inflammation in several models of acute neuronal damage and neurodegenerative diseases, including als, pd, migraines, and certain forms of dementia, is described. Also described is a method of relieving symptoms of als, pd, migraines, and certain forms of dementia, comprising administering to a subject in need thereof an effective amount of a glycosylated pacap..
The Arizona Board Of Regents On Behalf Of The University Of Arizona


06/16/16
20160166634 

Bioconjugates of synthetic apelin polypeptides


Or an amide, an ester or a salt thereof, wherein x1, x2, x3, x4, x5, x6, x7, x8, x9, x10, x11, x12 and x13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the apj receptor.

06/16/16
20160166619 

Treatment of retinal degeneration using progenitor cells


Methods and compositions for treating and reducing retinal degeneration using progenitor cells and conditioned media from progenitor cells, such as postpartum-derived cells are disclosed. Trophic factors and other agents secreted by the progenitor cells that protect retinal cells and inhibit apoptosis of retinal cells such as photoreceptor cells are also disclosed..
Janssen Biotech, Inc.


06/16/16
20160166613 

Methods for controlled elimination of therapeutic cells


The technology relates in part to methods for controlling elimination of therapeutic cells, for example, cells that express a chimeric antigen receptor. The technology further relates to a two-step method of controlling destruction of therapeutic cells in a patient following an adverse event.
Bellicum Pharmaceuticals, Inc.


06/16/16
20160166598 

A treating infection, sepsis and injury


The invention relates to a composition or method for treating at least one of infection, sepsis and injury or inducing a hypotensive state or a low pain or analgesic state in a subject susceptible to or suffering from at least one of infection, sepsis and injury. The composition comprises (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; and (ii) an antiarrhythmic agent or a local anaesthetic..
Hibernation Therapeutics, A Kf Llc


06/16/16
20160166591 

Compositions and methods to treat cardiac diseases


Phosphonate and phosphinate n-methanocarba derivatives of amp including their prodrug analogs are described. Mrs2339, a 2-chloro-amp derivative containing a (n)-methanocarba (bicyclo[3.1.0]hexane) ring system in place of ribose, activates p2x receptors, ligand-gated ion channels.
The United States Of America As Represented By The Secretary Department Of Health And Human Services


06/16/16
20160166576 

Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)


This invention relates to amidopyrazole compounds that are inhibitors of interieukin receptor-associated kinases, in particular irak-4, and are useful in the treatment of cellular proliferative diseases. Speifically (5-methylpyridin-2-yl)-1 h-pyrazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives are disclosed for use in the method of treating inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease and cancer..
Merck Sharp & Dohme Corp.


06/16/16
20160166569 

Method for treating skin thickening


Methods, compositions and products for treating or reducing skin thickening in a subject are described. Also described are methods of inhibiting a skin disorder induced by an uv-irradiation.
Galderma Research And Development


06/16/16
20160166566 

Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1h)-one derivatives having both muscarinic receptor antagonist and beta2 adrenergic receptor agonist activities


The present invention is directed to crystalline addition salts of (ii) 8-hydroxyquinolin-2(1h)-one derivatives and (ii) a dicarboxylic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.. .
Almirall, S.a.


06/16/16
20160166561 

Antipsychotic treatment based on drd2 or ankk1 snp genotype


The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (snp) associated with the dopamine receptor d2 (drd2) and/or ankyrin repeat and kinase domain containing 1 (ankk1) genes.. .
Vanda Pharmaceuticals, Inc.


06/16/16
20160166553 

Antimetastatic compounds


Screening methods for identifying compounds and compounds and pharmaceutical compositions for treating and preventing cancer are disclosed. The compounds affect signal transduction downstream of the met receptor..
Brigham Young University


06/16/16
20160166530 

Selective androgen receptor modulator and methods of use thereof


This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as duchenne muscular dystrophy or becker muscular dystrophy.. .
University Of Tennessee Research Foundation


06/16/16
20160166503 

Nasal drug products and methods of their use


Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided..
Lightlake Therapeutics, Inc.


06/16/16
20160166230 

X ray apparatus and operating the same


An x-ray apparatus which aligns an x-ray radiator with an x-ray detector, an x-ray apparatus which aligns an x-ray radiator with an x-ray detector while maintaining a source to image-receptor distance (sid) and a source to object distance (sod) therebetween, and methods of operating the x-ray apparatuses are provided.. .
Samsung Electronics Co., Ltd.


06/16/16
20160166121 

Shower receptors


A shower receptor includes a generally planar base surface, a deck surface, and a threshold surface. The generally planar base surface includes a drain opening.
Kohler Co.






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.4194

4998

0 - 1 - 110